|Bid||5,811.00 x 6100|
|Ask||5,811.00 x 13000|
|Day's range||5,806.00 - 5,896.45|
|52-week range||4,928.50 - 6,540.00|
|Beta (3Y monthly)||1.21|
|PE ratio (TTM)||34.21|
|Earnings date||26 Apr 2019|
|Forward dividend & yield||2.15 (3.51%)|
|1y target est||78.83|
Britain's FTSE 100 retreated slightly on Thursday after downbeat euro zone PMI data and as investors booked profits before the long Easter weekend. The FTSE 100 was down 0.2 percent and the FTSE 250 dropped ...
The blue-chip index ended a lacklustre session about flat, lagging its European peers, while the FTSE 250 held on to its six-month high with a 0.5 percent rise as a stronger pound also aided. The pound's gains followed upbeat comments from Britain's foreign minister Jeremy Hunt on talks between the government and the opposition Labour Party to find a consensus over Brexit.
Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Oncology portfolio growth trends During AstraZeneca’s (AZN) fourth-quarter earnings investor presentation, the company highlighted the potential of its oncology drug,
(Reuters) - Britain's main index lost ground on Monday as miners and oil majors fell, more than offsetting gains in bank stocks. The FTSE 100 was 0.2 percent lower, lagging its European and Asian counterparts, ...
Looking to invest in the new ISA year? i think these FTSE 100 (INDEXFTSE: UKX) income stocks are great ways to boost your shares portfolio.
Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Earnings guidance On its fourth-quarter earnings conference call, Pfizer (PFE) said that it expected its 2019 adjusted diluted EPS to be $2.82–$2.92, which doesn’t
Pfizer or AstraZeneca: Which Is a Better Pick in April?Stock price movementsOn April 11, Pfizer (PFE) closed at $42.27, 1.08% lower than its previous closing price, 22.99% higher than its 52-week low of $34.37, and 9.04% below its 52-week high of
AstraZeneca plc (LON: AZN) could offer a superior risk/reward ratio than forex trading in my opinion.
Hardman & Co Research 09-Apr-2019 / 16:10 GMT/BST * * *Hardman & Co Research: Global Pharmaceuticals: 2018 industry salesOver the last few weeks, most of the multi-national pharmaceutical companies have reported results for 2018, which has given us the opportunity to update our industry statistics and drug database. This report provides the first publication of global and US rankings of the top 15 drug companies for 2018. Comparisons are made with historical data to show how different company strategies have evolved. In addition, analysis has been provided for the evolution of therapeutic biopharmaceutical drugs, which saw sales rise 7.5% to $219bn, representing 25% of the market, and driven by growth in antibody-derived drugs.Companies (Ticker ISIN) mentioned in this report: AbbVie (ABBV US00287Y1091), Amgen (AMGN US0311621009), AstraZeneca (AZN GB0009895292), Bayer (BAYGN DE000BAY0017), Bristol-Myers Squibb (BMY US1101221083), Celgene (CELG US1510201049), Gilead Sciences (GILD US3755581036), GlaxoSmithKline (GSK GB0009252882), Johnson & Johnson (JNJ US4781601046), Eli Lilly (LLY US5324571083), Merck & Co (MRK US58933Y1055), Novartis (NOVN CH0012005267), Novo Nordisk (NOVO DK0060534915), Pfizer (PFE US7170811035), Roche (ROG CH0012032113), Sanofi (SAN FR0000120578), Takeda (4502 JP3463000004), Teva (TEVA US8816242098). Please click here for the full report:https://www.hardmanandco.com/research/corporate-research/global-pharmaceuticals-2018-industry-statistics/To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH www.hardmanandco.com Follow us on Twitter @HardmanandCo Contacts: Martin Hall +44 20 7194 7632 firstname.lastname@example.org Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer. * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! There are a number of reasons that attract investors towards large-cap companies such as AstraZeneca PLC (LON:AZN), with a ma...
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the investigational MEK 1/2 inhibitor and potential new medicine selumetinib.
The pan-European STOXX 600 index closed up 0.6 percent, having earlier hit session highs on encouraging signals from U.S.-China trade talks. The benchmark clocked its best quarter in four years, although gains in March were lower than in the previous two months as a bruising trade war which contributed to a slowdown in global growth and the chaos around Brexit hit sentiment. All sub-sectors within the pan-regional benchmark ended the quarter higher, led by the retail sector's 20 percent surge over the last three months.
The FTSE 100 added 0.6 percent to post its third straight month of gains and its first quarterly rise since June 2018. This led to blue-chip housebuilders, considered particularly sensitive to Brexit developments, hitting session lows.
The deal on the drug known as trastuzumab deruxtecan sent shares in Japan's Daiichi soaring 16 percent, its daily limit, to a record high on Friday. Daiichi's stock has climbed 45 percent this year on optimism about the treatment. Britain's AstraZeneca plans to use some of the proceeds of a $3.5 billion share issue to fund the deal.
LONDON (AP) — Shares in drug maker Daiichi Sankyo soared after AstraZeneca agreed to pay the Japanese company up to $6.9 billion as part of an agreement to develop and market a potentially "transformative" cancer treatment.
SECTORFOCUS BLOG That Friday feeling. Stocks are looking up Friday morning, with Dow Jones Industrial Average and Nasdaq Composite futures up 0.5% and the S&P 500 rising 0.4% ahead of the open. While global economic worries still remain, investors were optimistic that a fresh round of U.
The deal on the drug known as trastuzumab deruxtecan sent shares in Japan's Daiichi soaring 16 percent, its daily limit, to a record high on Friday. Daiichi's stock has climbed 45 percent this year on optimism about the treatment.
The answer is found in AstraZeneca Plc’s $6.9 billion oncology tie-up with Japan’s Daiichi Sankyo Co. Ltd. The partnership is AstraZeneca’s biggest in more than a decade. A couple of years ago, the drugmaker was linked to a possible takeover of Daiichi, a deal that would have been a stretch even then.
AstraZeneca will pay the Japanese drugmaker Daiichi Sankyo Co. $1.35 billion upfront to jointly develop and commercialize the cancer therapy trastuzumab deruxtecan, with as much as $5.6 billion in additional payments subject to sales milestones and other contingencies, the companies said late Thursday. The deal fuels a race among big drug companies to develop effective -- and lucrative -- new cancer treatments. With research breakthroughs like gene-editing and T-cell manipulation extending patients’ lives in unprecedented ways, the global market for cancer treatments has exploded to $133 billion annually and become the fiercest battleground in pharmaceuticals.
* STOXX 600 up 0.3 pct * Investors pin hopes on potential U.S.-China trade deal * H&M shines after results; TUI sinks after profit warning March 29 - Welcome to the home for real-time coverage of European ...